Key Highlights

  • PEMGARDA net product Revenue reached USD 14.3 million in the second quarter, a 21% increase on the USD 11.8 million of a year earlier, with USD 28.0 million for the half.
  • The June quarter ended with a net loss of USD 44.4 million, USD 0.14 per share, while the year-earlier figure was USD 14.7 million.
  • Cash and cash equivalents closed June at USD 160.1 million, down from USD 226.7 million at year end, and the Balance Sheet shows no debt.
  • VYD2311's pivotal DECLARATION Phase 3 study targets 2,301 participants, and management expects its top-line figures late in the third quarter of 2026.

No Second Quarter Call and the Revenue Base at Invivyd, Inc. (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD) will publish third quarter 2026 figures on November 16, 2026. The reference quarter shows PEMGARDA net product revenue of USD 14.3 million against USD 11.8 million, with a net loss of USD 44.4 million, or USD 0.14 per share, against USD 14.7 million a year before, when the per-share figure was USD 0.12. The company skipped a second quarter earnings call, and an investor call is planned after the DECLARATION study is complete.

Spending Growth and Pipeline Timing Behind Invivyd, Inc. (NASDAQ:IVVD)

Research and development spending rose to USD 29.4 million from USD 9.6 million, while selling, general and administrative expense climbed to USD 29.5 million from USD 16.6 million. Total operating expenses reached USD 60.1 million, which left an operating loss of USD 45.8 million, and no numeric financial guidance was given. Cash at Invivyd, Inc. (NASDAQ:IVVD) is expected to fund operations through the DECLARATION readout, keeping the company positioned for a possible VYD2311 launch. Invivyd, Inc. (NASDAQ:IVVD) guided top-line data from DECLARATION and LIBERTY for late in the third quarter of 2026, which makes that window the next major catalyst.

Equity Base, Accumulated Deficit and Emergency Authorization Risk for Invivyd, Inc. (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD) reported total Assets of USD 218.9 million at June 30, 2026, with liabilities of USD 37.8 million and Equity of USD 181.1 million. Shares outstanding stood at 294.8 million and the accumulated deficit reached USD 1,040.3 million. The most immediate threat is the termination of PEMGARDA's emergency use authorization, which the company was told about with twelve months' notice in July 2026, as the underlying declaration ends on June 29, 2027. Other risks include the DECLARATION outcome and whether Invivyd, Inc. (NASDAQ:IVVD) can raise funds beyond the readout.

Where Things Stand

Invivyd, Inc. (NASDAQ:IVVD) approaches the November 16, 2026 release with PEMGARDA sales of USD 14.3 million in the prior quarter and USD 160.1 million of cash at June 30, 2026, against operating expenses of USD 60.1 million in that quarter. The first half cash decline of USD 66.6 million implies, on a calculated basis, how fast the company is burning cash, which places the DECLARATION and LIBERTY readouts, due late in the third quarter of 2026, at the centre of funding plans and of a possible Biologics license application for VYD2311. The report should clarify how PEMGARDA's path to market will look after the emergency use authorization termination notice received in July 2026.